TSG genes (e.g., TP53, AXIN1 and PTEN, in the TSG gene subcomponent of VCaP and PC-3) were known to affect the aggressiveness of prostate cancer [41], corresponding to the Wnt signaling pathway, which is also a target pathway associated with Bortezomib [42]. This evidence concerns the gene AXIN1 and prostate carcinoma.